How India Exports Loperamide to the World

In the United States, loperamide is available both as an over-the-counter (OTC) and prescription medication. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for loperamide, indicating a competitive generic market. The most recent ANDA approvals for loperamide were granted in 2024. As of March 2026, there are no active FDA import alerts specifically targeting loperamide products from India, suggesting compliance with FDA standards among Indian exporters. Given that 58.4% of India's loperamide exports are destined for the U.S., it is imperative for Indian manufacturers to adhere strictly to FDA regulations to maintain market access.

In the European Union, loperamide is subject to national marketing authorizations, with oversight from the European Medicines Agency (EMA) and national competent authorities. The EMA has conducted periodic safety update report single assessments (PSUSAs) for loperamide, with the most recent assessment completed in May 2024, resulting in a maintenance decision. In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) oversees the authorization and regulation of loperamide products. Compliance with EU Good Manufacturing Practice (GMP) guidelines is mandatory for manufacturers exporting to these markets.

Loperamide is included in the World Health Organization's Model List of Essential Medicines, underscoring its importance in global health. The drug is recognized in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring standardized quality parameters across different markets.

In India, loperamide is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) has not set a ceiling price for loperamide, allowing market-driven pricing. For exports, the Directorate General of Foreign Trade (DGFT) requires a No Objection Certificate (NOC) for certain pharmaceutical products; however, loperamide is not currently listed among those requiring an export NOC.

The primary patents for loperamide have expired, leading to a robust generic market with multiple manufacturers producing the drug. This competitive landscape has resulted in a decrease in prices and increased accessibility globally.

In May 2024, the EMA completed a periodic safety update report single assessment (PSUSA) for loperamide, resulting in a maintenance decision, indicating no significant changes required in the product information. (ema.europa.eu)

In January 2025, the FDA updated import alerts to reinforce that all unauthorized e-cigarettes may be detained without physical examination. While this update does not directly pertain to loperamide, it reflects the FDA's ongoing efforts to regulate imported products rigorously.

In October 2024, the FDA and U.S. Customs and Border Protection announced the seizure of approximately three million units of misdeclared, unauthorized e-cigarette products. This action underscores the importance of accurate product declaration and compliance with FDA regulations for all imported pharmaceuticals, including loperamide.

In March 2022, the EMA published a list of nationally authorized medicinal products containing loperamide, providing transparency and guidance for manufacturers and healthcare professionals. (ema.europa.eu)

In March 2019, the EMA released scientific conclusions and grounds for variation, amendments to the product information, and a timetable for implementation for loperamide-containing products, reflecting ongoing pharmacovigilance efforts. (ema.europa.eu)

These developments highlight the dynamic regulatory environment surrounding loperamide and the necessity for manufacturers to stay informed and compliant with international standards to ensure continued market access.

India is a leading producer of Active Pharmaceutical Ingredients (APIs), including loperamide. However, the Indian pharmaceutical industry heavily relies on China for Key Starting Materials (KSMs) and intermediates essential for API synthesis. This dependency exposes the supply chain to risks associated with geopolitical tensions, trade restrictions, and production disruptions in China.

Recent events have exacerbated these vulnerabilities. In March 2026, the closure of the Strait of Hormuz due to escalating conflicts disrupted global shipping routes, leading to delays and increased costs for raw material imports. Additionally, China's stringent environmental regulations and periodic factory shutdowns have previously caused supply interruptions, highlighting the fragility of the current sourcing model.

Our proprietary trade data indicates that the top five Indian exporters of loperamide account for 69.8% of total exports, with RUBICON RESEARCH PRIVATE LIMITED alone contributing 55.6%. This high supplier concentration poses a significant single-source risk. Any operational issues, regulatory actions, or financial instability affecting these key suppliers could severely impact the global availability of loperamide.

To mitigate such risks, the Indian government introduced the Production Linked Incentive (PLI) scheme in 2020, aiming to boost domestic production of critical APIs and reduce reliance on imports. While the scheme has led to increased investments in API manufacturing, its full impact on diversifying the supplier base for loperamide remains to be seen.

The closure of the Strait of Hormuz in March 2026, following military escalations involving Iran, the United States, and Israel, has had profound effects on global shipping. The Strait, a vital conduit for approximately 20% of the world's oil supply, saw a dramatic reduction in vessel traffic, with tanker movements dropping by about 70% initially and eventually nearing zero. This disruption has led to increased shipping costs, delays, and heightened risks for cargo, including pharmaceutical products like loperamide.

Furthermore, the Red Sea and the Strait of Hormuz have become hotspots for maritime security threats, with multiple attacks on merchant vessels reported. Major shipping lines, including Maersk and CMA CGM, have suspended transits through these regions, opting for longer and more costly routes around the Cape of Good Hope. These developments have strained global supply chains and could lead to shortages of critical medications if alternative logistics solutions are not promptly implemented.

• Diversify Supplier Base: Encourage the development of alternative suppliers for loperamide and its raw materials to reduce dependency on a limited number of exporters.

• Enhance Domestic Production: Leverage the PLI scheme to bolster domestic manufacturing capabilities for APIs and KSMs, thereby decreasing reliance on imports.

• Strengthen Supply Chain Resilience: Develop contingency plans, including alternative shipping routes and strategic stockpiling, to mitigate the impact of geopolitical disruptions.

• Monitor Geopolitical Developments: Establish a dedicated team to track and assess geopolitical events that could affect supply chains, enabling proactive risk management.

• Collaborate with Regulatory Bodies: Engage with international regulatory agencies to ensure compliance and facilitate swift responses to potential shortages or disruptions.

RISK_LEVEL: HIGH